The company plans to use the financing to expand the accessibility of its Haystack Duo testing service. The financing round was led by Catalio Capital Management, the venture capital group that co-founded Haystack through its private equity, according to a Nov. 16 Haystack news release.
The company’s testing services work to detect MRD, residual tumor DNA molecules left in the body after treatment.
“Detecting MRD has long been akin to looking for a needle in a haystack — we’re searching for a small number of tumor-derived DNA molecules in a sea of normal molecules in a blood sample. If residual disease is detected, the patient journey can be transformed to greatly improve the likelihood of clinical benefit, and ultimately, save lives,” Haystack President and CEO Dan Edelstein said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
